KAI Pharmaceuticals

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI’s lead product candidate, KAI-9803, is currently in a Phase 2b study...

Total money raised: $35M

94080 270 Littlefield Avenue

South San Francisco
South San Francisco

Phone: 650-244-1100

Updated on Feb 13, 2013
KAI Pharmaceuticals at CrunchBase
Daria Mochly-Rosen Founder / CSO / Scientific Consultant / Chairperson, Scientific Advisory Board Director
Paul Sekhri member of the boards of directors
Leon Chen Founder
John Walker Executive Chairman / CEO
Kristine M. Ball senior vice president of finance and administration and chief financial officer

April, 2012

KAI Pharmaceuticals was acquired by Amgen
for $315M

UPDATED: Amgen snags KAI Pharma's CKD program in $315M buyout

May, 2006

KAI Pharmaceuticals raised $35M in a Series B round from Investor Growth Capital, Aberdare Ventures, Skyline Ventures, InterWest Partners, InterSouth Partners, Delphi Ventures, and MDS Capital

KAI Pharmaceuticals Completes $35 Million Series B Financing